Business Context and Reporting Period
Company: Broadway Financial Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: July 2, 2012
Event: Entry into definitive material agreements and unregistered sales of equity securities involving company insiders.
Key Financial Metrics
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, margins, or debt levels. The financial data provided is limited to the specific equity transaction details:
- Total Shares Sold: 115,386 shares of common stock
- Aggregate Purchase Price: $150,000
- Price Per Share: $1.30 (determined as market value per NASDAQ Listing Rule 5005(a)(22))
- Payment Method: Cash paid on July 2, 2012
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. The material change reported is the increase in insider ownership through the private placement of 115,386 shares to six individuals (five directors and the President/CEO).
Guidance, Outlook, and Unusual Items
Transaction Structure: The sales were conducted as private placements to accredited investors under Section 4(2) of the Securities Act and Regulation D.
Price Adjustment Clause: A unique provision requires purchasers to return shares if the Corporation sells shares in a recapitalization transaction within three months at a price higher than $1.30. In such an event, the purchase price would be adjusted to the higher price.
Contingencies: The stock purchases were not contingent on the completion of any other transaction.
Investor Verification Checklist
- Verify the current market price of Broadway Financial Corporation stock relative to the $1.30 transaction price.
- Confirm the updated insider ownership percentages following the purchase of 115,386 shares.
- Monitor for any recapitalization transactions occurring within three months of July 2, 2012, which could trigger the share return clause.
- Review subsequent filings for any changes in the company's capital structure or liquidity position resulting from the $150,000 cash infusion.